2018
DOI: 10.1080/2162402x.2018.1484980
|View full text |Cite
|
Sign up to set email alerts
|

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts

Abstract: Multiple soluble factors including proteins (in particular chemokines), non-proteinaceous factors released by dead cells, as well as receptors for such factors (in particular chemokine receptors, formyl peptide receptors and purinergic receptors), influence the recruitment of distinct cell subsets into the tumor microenvironment. We performed an extensive bioinformatic analysis on tumor specimens from 5953 cancer patients to correlate the mRNA expression levels of chemotactic factors/receptors with the density… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(18 citation statements)
references
References 84 publications
(62 reference statements)
0
17
0
Order By: Relevance
“…Consistent with our findings, the CXCL-9/CXCL-10/ CXCL-11-CXCR3 axis has been reported to lead to enhanced tumor growth restriction by recruitment of CD8 + T cells (CTLs), NK cells and macrophages. [27][28][29][30][31] In mouse models, CXCL-11, as an adjuvant to oncolytic virus-based treatments, could significantly enhance their anti-tumor efficacy, 29 and CXCL-11-Fc fusions enhanced recruitment of antigen-specific CD8 + T cells. 32 Furthermore, secretion of these three mediators by monocytes, endothelial cells, fibroblasts and cancer cells was enhanced through transcriptional activation of STAT1 and NFκB, caused by IFNγ and TNFα working in synergy.…”
Section: Discussionmentioning
confidence: 99%
“…Consistent with our findings, the CXCL-9/CXCL-10/ CXCL-11-CXCR3 axis has been reported to lead to enhanced tumor growth restriction by recruitment of CD8 + T cells (CTLs), NK cells and macrophages. [27][28][29][30][31] In mouse models, CXCL-11, as an adjuvant to oncolytic virus-based treatments, could significantly enhance their anti-tumor efficacy, 29 and CXCL-11-Fc fusions enhanced recruitment of antigen-specific CD8 + T cells. 32 Furthermore, secretion of these three mediators by monocytes, endothelial cells, fibroblasts and cancer cells was enhanced through transcriptional activation of STAT1 and NFκB, caused by IFNγ and TNFα working in synergy.…”
Section: Discussionmentioning
confidence: 99%
“…CXCL9 and CXCL10 play a critical role in the recruitment of T and NK cells into tumors of various origins and it has been demonstrated that blockade of either them or their receptor CXCR3, impairs recruitment of adoptively transferred T cells into melanoma tumors (Chheda et al 2016;Mikucki et al 2015;Stoll et al 2018).…”
Section: Role Of Chemokines In Tumor Immunology and In Immunotherapymentioning
confidence: 99%
“…Breast cancer [19,75] TAMs [47,64,75] Cervical cancer [19] Lung cancer [19] Multiple myeloma [19] Osteosarcoma [76] Pancreatic cancer [19] Prostate cancer [19] CCR6 CCL20…”
Section: Ccl4 Ccl5 Ccl8mentioning
confidence: 99%
“…A comprehensive meta-analysis of more than 5000 tumor specimens from patients with breast, colorectal, lung, ovary, head and neck carcinomas, as well as melanomas, recently revealed that a universal pattern of correlation exists between the relative abundance of distinct leukocyte subsets infiltrating the tumors and the expression of individual chemokines-receptors, regardless of the cancer type and localization [75]. Indeed, CCR1, CCR2, CCR5, CXCR4, CCL18, CCL19, CCL21, and CXCL12 expression has been identified to positively correlate with immune infiltration of breast and colorectal carcinomas, non-small cell lung cancer and melanomas [75].…”
Section: Chemokines and Tumor Immunitymentioning
confidence: 99%
See 1 more Smart Citation